Lieping Chen
Yale University
H-index: 142
North America-United States
Description
Lieping Chen, With an exceptional h-index of 142 and a recent h-index of 84 (since 2020), a distinguished researcher at Yale University, specializes in the field of Immunology, tumor immunology, immunotherapy.
His recent articles reflect a diverse array of research interests and contributions to the field:
Increased Lymphocyte Infiltration in NSCLC Neoadjuvant Chemo-Immunotherapy Non-responders: A Biomarker of T-Cell Dysfunction and Prognosis?
Immune Inhibitory Molecule PD-1 Homolog (VISTA) Colocalizes with CD11b Myeloid Cells in Melanoma and Is Associated with Poor Outcomes
Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target
PD-1H/VISTA mediates immune evasion in acute myeloid leukemia
CD137 (4-1BB)-based cancer immunotherapy on its 25th anniversary
B7-H5, a costimulatory polypeptide
Phase I study of single-agent anti–programmed death-1 (MDX-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates
Author Correction: Programmed death one homolog maintains the pool size of regulatory T cells by promoting their differentiation and stability
Professor Information
University | Yale University |
---|---|
Position | Department of Immunobiology |
Citations(all) | 109082 |
Citations(since 2020) | 42156 |
Cited By | 80442 |
hIndex(all) | 142 |
hIndex(since 2020) | 84 |
i10Index(all) | 401 |
i10Index(since 2020) | 283 |
University Profile Page | Yale University |
Research & Interests List
Immunology
tumor immunology
immunotherapy
Top articles of Lieping Chen
Increased Lymphocyte Infiltration in NSCLC Neoadjuvant Chemo-Immunotherapy Non-responders: A Biomarker of T-Cell Dysfunction and Prognosis?
After proven efficacy in the advanced and metastatic setting in non-small-cell lung cancer (NSCLC), the use of immune checkpoint inhibitors that target the programmed cell death-1/programmed cell death-ligand 1 (PD-1/PD-L1) pathway is rapidly becoming standard-of-care in the perioperative setting for locally advanced patients. The Checkmate-816 trial changed the treatment paradigm for stage II and stage III disease by demonstrating improvements in complete pathologic response rates and improved event-free survival rates at 24 months among patients treated with 3 cycles of neoadjuvant nivolumab plus chemotherapy versus chemotherapy alone prior to surgical resection. 1 PD-L1 expression and tumor mutational burden (TMB) are commonly used, but imperfect biomarkers, to predict clinical response to anti-PD therapy in NSCLC. 2–4 While increased PD-L1 protein expression in tumors correlates with …
Authors
Gavitt A Woodard,Christina Cho,Lieping Chen
Journal
Annals of Surgical Oncology
Published Date
2024/1
Immune Inhibitory Molecule PD-1 Homolog (VISTA) Colocalizes with CD11b Myeloid Cells in Melanoma and Is Associated with Poor Outcomes
Tumors evade immunity through the overexpression of immune inhibitory molecules in the tumor microenvironment such as PD-L1/B7-H1. An immune inhibitory molecule named PD-1 homolog (also known as V-domain Ig-containing suppressor of T cell activation [VISTA]) functions to control both T cells and myeloid cells. Current clinical trials using anti-VISTA–blocking agents for treatment of cancer are ongoing. We sought to determine the extent of VISTA expression in primary cutaneous melanomas (n = 190), identify the critical cell types expressing VISTA, and correlate its expression with PD-L1 expression using multiplexed quantitative immunofluorescence. Within the tumor subcompartments, VISTA is most highly expressed on CD11b myeloid cells, and PD-L1 is most highly expressed on CD68 myeloid cells in our melanoma cohort. There is little correlation between VISTA and PD-L1 expression intensity …
Authors
Matthew D Vesely,Michal Kidacki,Patricia Gaule,Swati Gupta,Nay Nwe Nyein Chan,Xue Han,Jacky T Yeung,Lieping Chen
Journal
Journal of Investigative Dermatology
Published Date
2024/1/1
Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target
The invention features methods of diagnosis by assessing B7-H1 expression in a tissue from a subject that has, or is suspected of having, cancer, methods of treatment with agents that interfere with B7-H1-receptor interaction, methods of selecting candidate subjects likely to benefit from cancer immunotherapy, and methods of inhibiting expression of B7-H1.
Published Date
2022/2/8
PD-1H/VISTA mediates immune evasion in acute myeloid leukemia
Acute myeloid leukemia (AML) presents a pressing medical need in that it is largely resistant to standard chemotherapy as well as modern therapeutics, such as targeted therapy and immunotherapy, including anti–programmed cell death protein (anti-PD) therapy. We demonstrate that programmed death-1 homolog (PD-1H), an immune coinhibitory molecule, is highly expressed in blasts from the bone marrow of AML patients, while normal myeloid cell subsets and T cells express PD-1H. In studies employing syngeneic and humanized AML mouse models, overexpression of PD-1H promoted the growth of AML cells, mainly by evading T cell–mediated immune responses. Importantly, ablation of AML cell-surface PD-1H by antibody blockade or genetic knockout significantly inhibited AML progression by promoting T cell activity. In addition, the genetic deletion of PD-1H from host normal myeloid cells inhibited AML …
Authors
Tae Kon Kim,Xue Han,Qianni Hu,Esten N Vandsemb,Carly M Fielder,Junshik Hong,Kwang Woon Kim,Emily F Mason,R Skipper Plowman,Jun Wang,Qi Wang,Jian-Ping Zhang,Ti Badri,Miguel F Sanmamed,Linghua Zheng,Tianxiang Zhang,Jude Alawa,Sang Won Lee,Amer M Zeidan,Stephanie Halene,Manoj M Pillai,Namrata S Chandhok,Jun Lu,Mina L Xu,Steven D Gore,Lieping Chen
Journal
The Journal of clinical investigation
Published Date
2024/2/1
CD137 (4-1BB)-based cancer immunotherapy on its 25th anniversary
Twenty-five years ago, we reported that agonist anti-CD137 monoclonal antibodies eradicated transplanted mouse tumors because of enhanced CD8+ T-cell antitumor immunity. Mouse models indicated that anti-CD137 agonist antibodies synergized with various other therapies. In the clinic, the agonist antibody urelumab showed evidence for single-agent activity against melanoma and non-Hodgkin lymphoma but caused severe liver inflammation in a fraction of the patients. CD137's signaling domain is included in approved chimeric antigen receptors conferring persistence and efficacy. A new wave of CD137 agonists targeting tumors, mainly based on bispecific constructs, are in early-phase trials and are showing promising safety and clinical activity. Significance CD137 (4-1BB) is a costimulatory receptor of T and natural killer lymphocytes whose activity can be exploited in …
Authors
Ignacio Melero,Miguel F Sanmamed,Javier Glez-Vaz,Carlos Luri-Rey,Jun Wang,Lieping Chen
Published Date
2023/3/1
B7-H5, a costimulatory polypeptide
B7-H5 costimulatory polypeptides, nucleic acids encoding such polypeptides, and methods for using the polypeptides and nucleic acids to enhance a T cell response are provided herein.
Published Date
2023/9/19
Phase I study of single-agent anti–programmed death-1 (MDX-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates
PurposeProgrammed death-1 (PD-1), an inhibitory receptor expressed on activated T cells, may suppress antitumor immunity. This phase I study sought to determine the safety and tolerability of anti–PD-1 blockade in patients with treatment-refractory solid tumors and to preliminarily assess antitumor activity, pharmacodynamics, and immunologic correlates.Patients and MethodsThirty-nine patients with advanced metastatic melanoma, colorectal cancer (CRC), castrate-resistant prostate cancer, non–small-cell lung cancer (NSCLC), or renal cell carcinoma (RCC) received a single intravenous infusion of anti–PD-1 (MDX-1106) in dose-escalating six-patient cohorts at 0.3, 1, 3, or 10 mg/kg, followed by a 15-patient expansion cohort at 10 mg/kg. Patients with evidence of clinical benefit at 3 months were eligible for repeated therapy.ResultsAnti–PD-1 was well tolerated: one serious adverse event, inflammatory colitis …
Authors
Julie R Brahmer,Charles G Drake,Ira Wollner,John D Powderly,Joel Picus,William H Sharfman,Elizabeth Stankevich,Alice Pons,Theresa M Salay,Tracee L McMiller,Marta M Gilson,Changyu Wang,Mark Selby,Janis M Taube,Robert Anders,Lieping Chen,Alan J Korman,Drew M Pardoll,Israel Lowy,Suzanne L Topalian
Journal
Journal of Clinical Oncology
Published Date
2023/2/1
Author Correction: Programmed death one homolog maintains the pool size of regulatory T cells by promoting their differentiation and stability
“We thank Beth Cadugan for editing the manuscript, Dr. Zhiyong Guo (The first affiliated hospital, Sun Yat-sen University) for generously sharing the Foxp3 (GFP) knock-in mice, and Mr. Xiaobo Li for providing the technical support of cell sorting. This study partially fulfills the requirement of the Ph. D. degree at the Graduate School of Sun Yat-sen University School of Medicine for Qi Wang and Jianwei He. This work is supported in part by the 985 project grant from Sun Yat-sen University, Guangdong Province Innovative Research Program Project 2011Y035, PRC; National Institutes of Health grants P50 CA177444, P30 CA016359, P50 CA17744415 and P30 CAO16359, and an endowment from the United Technologies Corporation, USA.” should read:
Authors
Qi Wang,Jianwei He,Dallas B Flies,Liqun Luo,Lieping Chen
Journal
Scientific Reports
Published Date
2023/7/18
Professor FAQs
What is Lieping Chen's h-index at Yale University?
The h-index of Lieping Chen has been 84 since 2020 and 142 in total.
What are Lieping Chen's top articles?
The articles with the titles of
Increased Lymphocyte Infiltration in NSCLC Neoadjuvant Chemo-Immunotherapy Non-responders: A Biomarker of T-Cell Dysfunction and Prognosis?
Immune Inhibitory Molecule PD-1 Homolog (VISTA) Colocalizes with CD11b Myeloid Cells in Melanoma and Is Associated with Poor Outcomes
Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target
PD-1H/VISTA mediates immune evasion in acute myeloid leukemia
CD137 (4-1BB)-based cancer immunotherapy on its 25th anniversary
B7-H5, a costimulatory polypeptide
Phase I study of single-agent anti–programmed death-1 (MDX-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates
Author Correction: Programmed death one homolog maintains the pool size of regulatory T cells by promoting their differentiation and stability
...
are the top articles of Lieping Chen at Yale University.
What are Lieping Chen's research interests?
The research interests of Lieping Chen are: Immunology, tumor immunology, immunotherapy
What is Lieping Chen's total number of citations?
Lieping Chen has 109,082 citations in total.